Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued on Monday. They presently have a $6.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 261.45% from the stock’s current price.

Separately, Zacks Investment Research cut Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, January 5th.

Shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) traded up 7.79% on Monday, hitting $1.66. The company’s stock had a trading volume of 3,994,589 shares. The stock’s 50 day moving average is $1.17 and its 200-day moving average is $1.14. The company’s market cap is $137.56 million. Catalyst Pharmaceuticals has a 52 week low of $0.51 and a 52 week high of $1.81.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/20/catalyst-pharmaceuticals-inc-cprx-given-buy-rating-at-hc-wainwright.html

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its earnings results on Wednesday, March 15th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.02. On average, equities research analysts anticipate that Catalyst Pharmaceuticals will post ($0.26) earnings per share for the current year.

Your IP Address:

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Baker BROS. Advisors LP acquired a new position in Catalyst Pharmaceuticals during the third quarter valued at about $5,561,000. Kingdon Capital Management L.L.C. acquired a new position in Catalyst Pharmaceuticals during the fourth quarter valued at about $794,000. Royal Bank of Canada acquired a new position in Catalyst Pharmaceuticals during the second quarter valued at about $117,000. Finally, Berson & Corrado Investment Advisors LLC raised its position in Catalyst Pharmaceuticals by 76.1% in the third quarter. Berson & Corrado Investment Advisors LLC now owns 181,900 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 78,600 shares during the period. Hedge funds and other institutional investors own 28.13% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

5 Day Chart for NASDAQ:CPRX

Receive News & Ratings for Catalyst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.